  | Costanza, B., Umelo, I., Bellier, J., Turtoi, A., & Castronovo, V. (2017). Stromal Modulators of TGF-β in Cancer. Journal of Clinical Medicine. doi:10.3390/jcm6010007  Peer Reviewed verified by ORBi |
| Umelo, I., Noeparast, A., Chen, G., Renard, M., Geers, C., Vansteenkiste, J., Giron, P., De Wever, O., Teugels, E., & De Greve, J. (January 2016). Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. Oncotarget, 7 (3), 3068-83. doi:10.18632/oncotarget.6585 Peer reviewed |
| Umelo, I., De Wever, O., Kronenberger, P., Van Deun, J., Noor, A., Singh, K., Teugels, E., Chen, G., Bracke, M., & De Greve, J. (2015). Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade. Oncotarget, 6 (24), 20132-44. doi:10.18632/oncotarget.3853 Peer reviewed |
| Umelo, I., Wever, O. D., Kronenberger, P., Noor, A., Teugels, E., Chen, G., Bracke, M., & Greve, J. D. (2015). Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells. Lung Cancer, 90 (2), 167-74. doi:10.1016/j.lungcan.2015.08.008 Peer Reviewed verified by ORBi |
| Chen, G., Noor, A., Kronenberger, P., Teugels, E., Umelo, I., & De Greve, J. (2013). Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS ONE, 8 (3), 59708. doi:10.1371/journal.pone.0059708 Peer Reviewed verified by ORBi |
| Chen, G., Umelo, I., Lv, S., Teugels, E., Fostier, K., Kronenberger, P., Dewaele, A., Sadones, J., Geers, C., & De Greve, J. (2013). miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS ONE, 8 (3), 60317. doi:10.1371/journal.pone.0060317 Peer Reviewed verified by ORBi |
| Chen, G., Kronenberger, P., Teugels, E., Umelo, I., & De Greve, J. (2013). Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochemical and Biophysical Research Communications, 431 (3), 623-9. doi:10.1016/j.bbrc.2012.12.070 Peer reviewed |
| Chen, G., Kronenberger, P., Teugels, E., Umelo, I., & De Greve, J. (2012). Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Medicine, 10, 28. doi:10.1186/1741-7015-10-28 Peer Reviewed verified by ORBi |
| De Greve, J., Teugels, E., Geers, C., Decoster, L., Galdermans, D., De Mey, J., Everaert, H., Umelo, I., In't Veld, P., & Schallier, D. (2012). Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer, 76 (1), 123-7. doi:10.1016/j.lungcan.2012.01.008 Peer Reviewed verified by ORBi |
| Chen, G., Kronenberger, P., Umelo, I., Teugels, E., & De Greve, J. (2010). Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Analytical Biochemistry, 398 (2), 266-8. doi:10.1016/j.ab.2009.11.034 Peer Reviewed verified by ORBi |